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The arterial media comprises vascular smooth muscle cells (VSMCs; ≈30%) and extracellular matrix (ECM, ≈70%), 
including collagen, elastin, and matrix glycosaminoglycans. The 
intima in atherosclerosis also comprises both cellular and non-
cellular components, and advanced plaques show large acellular 
regions. VSMCs synthesize both filamentous and nonfilamen-
tous ECM components, and chronic low-level VSMC apoptosis 
promotes medial degeneration characterized by VSMC loss, 
elastin fragmentation, and ECM degradation.1 Medial VSMC 
apoptosis, elastin fragmentation, and matrix degradation also 
occur in arterial aneurysms, vascular injury, and vascular remod-
eling. ECM degradation after VSMC apoptosis may be because 
of impaired synthesis from fewer VSMCs, increased degrada-
tion during VSMC apoptosis, or both processes triggered by 
the same stimuli. Indeed, macrophages induce VSMC apopto-
sis and secrete MMP (matrix metalloproteinase) enzymes that 
degrade ECM in atherosclerosis. However, macrophages are 
frequently absent in medial degeneration or vascular remodel-
ing, and the mechanisms that might directly link VSMC apopto-
sis with ECM degradation in vascular disease are unclear.
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Objective—Vascular smooth muscle cell (VSMC) apoptosis accelerates atherosclerosis and promotes breakdown of the 
extracellular matrix, but the mechanistic links between these 2 processes are unknown. The forkhead protein FOXO3a 
(forkhead transcription factor O subfamily member 3a) is activated in human atherosclerosis and induces a range of 
proapoptotic and other transcriptional targets. We, therefore, determined the mechanisms and consequences of FOXO3a 
activation in atherosclerosis and arterial remodeling after injury.
Approach and Results—Expression of a conditional FOXO3a allele (FOXO3aA3ER) potently induced VSMC apoptosis, 
expression and activation of MMP13 (matrix metalloproteinase 13), and downregulation of endogenous TIMPs (tissue 
inhibitors of MMPs). mmp13 and mmp2 were direct FOXO3a transcriptional targets in VSMCs. Activation of endogenous 
FOXO3a also induced MMP13, extracellular matrix degradation, and apoptosis, and MMP13-specific inhibitors and 
fibronectin reduced FOXO3a-mediated apoptosis. FOXO3a activation in mice with VSMC-restricted FOXO3aA3ER 
induced MMP13 expression and activity and medial VSMC apoptosis. FOXO3a activation in FOXO3aA3ER/ApoE−/− 
(apolipoprotein E deficient) mice increased atherosclerosis, increased necrotic core and reduced fibrous cap areas, and 
induced features of medial degeneration. After carotid artery ligation, FOXO3a activation increased VSMC apoptosis, 
VSMC proliferation, and neointima formation, all of which were reduced by MMP13 inhibition.
Conclusions—FOXO3a activation induces VSMC apoptosis and extracellular matrix breakdown, in part, because of 
transcriptional activation of MMP13. FOXO3a activation promotes atherosclerosis and medial degeneration and 
increases neointima after injury that is partly dependent on MMP13. FOXO3a-induced MMP activation represents a 
direct mechanistic link between VSMC apoptosis and matrix breakdown in vascular disease.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38:555-565. 
DOI: 10.1161/ATVBAHA.117.310502.)
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Apoptosis is regulated via integration of pro and anti-
apoptotic signals. IGF-1 (insulin-like growth factor 1) is a 
potent survival factor for VSMCs2,3 through activation of 
the serine/theronine kinase Akt1 (serine threonine kinase 
of the Akt family). Akt1 protects against VSMC apoptosis 
and atherogenesis and also promotes fibrous cap forma-
tion and reduces necrotic cores.4,5 Akt1-induced protection 
is due in part via phosphorylation of the FOXO (forkhead 
transcription factor O) subfamily, leading to their associa-
tion with 14-3-3 proteins and retention in the cytoplasm; 
survival factor withdrawal leads to FOXO dephosphoryla-
tion, nuclear translocation, and activation.6,7 The mamma-
lian FOXO subfamily includes 4 members: FOXO1, 3a, 4, 
and 6.8,9 FOXOs are involved in a complicated signaling 
network, and their transcriptional targets regulate multiple 
physiological and pathological processes, including can-
cer, development, mitochondria-dependent and indepen-
dent oxidative stress, DNA repair, and cell cycle arrest.10 
However, FOXOs are strictly cell type-specific, and their 
effects depend on expression levels. For example, FOXO3a 
protects cells from oxidative stress and DNA damage, 
but sustained FOXO3a activation leads to apoptosis, and 
FOXO3a activation induces apoptosis in hematopoietic 
cells but cell cycle arrest in most other cell types.11,12
VSMCs in human atherosclerotic plaques show reduced 
IGF-1 receptor expression13 and phosphorylation of both Akt 
and FOXO3a, indicating FOXO3a activation.14 Massive over-
expression of FOXO3a via adenovirus-mediated gene trans-
fer inhibits neointimal hyperplasia by promoting p27 (cyclin 
dependent kinase inhibitor p27)-mediated cell cycle arrest and 
apoptosis11,12 and prevents VSMC migration through inhibition 
of CYR61 (cysteine-rich angiogenic inducer 61).15 However, 
the functional consequences of activation of endogenous or 
low levels of FOXO3a in atherosclerosis, and in particular 
whether FOXO3a links VSMC apoptosis and ECM degrada-
tion, are unknown.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
FOXO3a Induces VSMC Apoptosis and 
MMP13 Expression and Activation
We first generated rat VSMCs expressing N-terminal 
haemagglutinin-tagged FOXO3aA3ER.5 FOXO3a is inhibited 
by Akt phosphorylation of 3 serine residues, but their mutation 
to alanine renders FOXO3a insensitive to Akt (FOXO3aA3). 
FOXO3aA3ER is thus a hydroxytamoxifen-activatable 
human FOXO3aA3 allele allowing temporal FOXO3a activa-
tion. FOXO3aA3ER was inactive without hydroxytamoxifen, 
but hydroxytamoxifen induced FOXO3a targets such as bim, 
caused FOXO3a translocation to the nucleus within 4 hours, 
and induced >80% apoptosis within 24 hours, defined by 
chromatin condensation on DAPI (4’,6-diamidino-2-phenyl-
indole) staining and characteristic appearances on digital vid-
eomicroscopy (Figure I in the online-only Data Supplement). 
To examine downstream signaling after FOXO3aA3ER acti-
vation, we examined mRNA expression from FOXO3aA3ER 
VSMCs and control wild-type rat VSMCs 4 hours after 
hydroxytamoxifen treatment by microarray5 (Table I in the 
online-only Data Supplement; full data at http://www.bioc.
cam.ac.uk/littlewood/foxo3a-microarray/view). Of 27 342 
genes, 3467 were upregulated and 4412 genes downregulated 
4 hours after hydroxytamoxifen in FOXO3aA3ER VSMCs. 
In addition to bona fide FOXO3a target genes (bim, gadd45α, 
p27), other apoptosis and antiapoptosis genes, such as bcl2, 
were upregulated, demonstrating the complexity of FOXO3a 
regulation of apoptosis. However, several MMPs were also 
upregulated, and downregulated genes included those associ-
ated with ECM attachment and MMP inhibitors. In particular, 
there was marked induction of mmp13 (371-fold) and down-
regulation of timp3 (27-fold), which would result in markedly 
increased MMP activity, especially MMP13 (Table I in the 
online-only Data Supplement).
To confirm the microarray data, we examined mmp13 
mRNA and protein by  quantitative polymerase chain reac-
tion and Western blotting after hydroxytamoxifen treatment 
≤24 hours. FOXO3a activation in FOXO3aA3ER VSMCs 
induced mmp13 mRNA in a time-dependent pattern (78-fold 
at 12 hours; Figure 1A), with a lower but significant induction 
of other FOXO3a targets (gadd45α [21-fold], bim [18.9-fold], 
p27 [11.4-fold], apaf1 [5.3-fold], p21 [4.2-fold], and cyr-61 
[3.6-fold]). MMP13 protein expression was increased both in 
conditioned media and cell lysates, with MMP13 activation 
demonstrated by protein cleavage from its proform (60 kd) 
to active intermediate form (Figure 1B). Zymography of the 
conditioned media confirmed that MMP13 showed the larg-
est change in activity after hydroxytamoxifen (Figure 1C), 
and immunoprecipitation of the conditioned media with an 
MMP13 antibody and subsequent zymography showed sig-
nificantly increased MMP13 activity after hydroxytamoxifen 
(Figure 1D). In situ zymography showed that hydroxytamoxi-
fen induced degradation of fluorescent-labeled fluorogenic 
dye-quenched gelatin around FOXO3aA3ER cells (Figure 1E). 
FOXO3a activation also inhibited expression of TIMP1/2/3 
(tissue inhibitors of MMP1/2/3) in cell lysates, with a particu-
larly marked time-dependent reduction in TIMP3 (Figure II in 
the online-only Data Supplement).
Nonstandard Abbreviations and Acronyms
Akt serine threonine kinase of the Akt family
ApoE−/− apolipoprotein E deficient
CYR61 cysteine-rich angiogenic inducer 61
ECM extracellular matrix
FOXO3a forkhead transcription factor O subfamily member 3a
GADD45 growth arrest and DNA damage gene
IGF-1 insulin-like growth factor 1
MMP matrix metalloproteinase
p27 cyclin dependent kinase inhibitor p27
SF serum free
SFGF serum and glucose withdrawal
TIMP tissue inhibitor of matrix metalloproteinase
VSMC vascular smooth muscle cell
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MMP13 Is a Bona Fide FOXO3a Target in VSMCs
The rapid induction of MMP13 in FOXO3aA3ER VSMCs 
suggests that MMP13 is a direct FOXO3a transcriptional 
target. Indeed, mmp3, mmp9, and mmp2 promoters show 
putative FOXO-binding sites, although their activity var-
ies markedly according to cell type.16,17 We cotransfected 
full-length (−1→−1600 promoter region relative to the tran-
scriptional start site) MMP13-, MMP2-, MMP3-, or MMP9-
luciferase plasmids with pRenilla-cytomegalovirus into 
FOXO3aA3ER VSMCs (Table II in the online-only Data 
Supplement) and a forkhead response element promoter-luc 
reporter as a positive control. Hydroxytamoxifen induced 
luciferase activity after transfection with the forkhead response 
element promoter, full-length MMP13 and MMP2 but not 
MMP9 and MMP3 constructs (Figure 2A). Point mutation of 
the FOXO3a DNA-binding motif (Figure III in the online-only 
Data Supplement) markedly reduced MMP13 promoter activ-
ity (Figure 2B). To confirm FOXO3a binding to the MMP13 
promoter, FOXO3aA3ER VSMCs were treated with hydroxy-
tamoxifen for 24 hours and chromatin immunoprecipitation 
performed with either rabbit IgG or a FOXO3a-specific anti-
body. Hydroxytamoxifen treatment of FOXO3aA3ER VSMCs 
induced FOXO3a binding to the MMP13 and GADD45α 
(growth arrest and DNA damage gene) promoters (Figure IV 
in the online-only Data Supplement). FOXO3a siRNA reduced 
expression of FOXO3aA3ER and endogenous FOXO3a protein 
without effects on expression of FOXO1 and FOXO4 (Figure 
IV in the online-only Data Supplement). FOXO3a siRNA 
also reduced MMP13 expression in conditioned media and 
cell lysates (Figure 2C) and MMP13 activity by zymography 
(Figure 2D), confirming that MMP13 is a target of FOXO3a.
FOXO3a Activation at Endogenous Levels 
Induces MMPs and ECM Degradation
Although FOXO3a overexpression studies in rodent cells 
can elucidate possible FOXO3a targets and functional activ-
ity, FOXO3a targets and effects depend on cell type, species, 
level of expression, and activity. We, therefore, examined 
the effects of activation of endogenous levels of FOXO3a 
in human VSMCs by withdrawal of serum±glucose, which 
reduces Akt-dependent phosphorylation.13 Transfer of human 
VSMCs to serum-free (SF) medium reduced phosphorylated 
FOXO3a with no change in total FOXO3a; in contrast, com-
plete loss of p-FOXO3a was seen after serum and glucose 
withdrawal (SFGF), indicating full activation of endogenous 
FOXO3a (Figure 2E). SFGF induced almost complete nuclear 
localization of FOXO3a and increased mRNA expression of 
bim (1.5-fold) and gadd45α (18-fold), but not mmp2, with a 
36-fold increase in mmp13 mRNA (Figure V in the online-
only Data Supplement). SFGF also induced FOXO3a binding 
to the mmp13 and bim promoters (Figure V in the online-
only Data Supplement). Compared with SF, SFGF increased 
MMP13 protein expression and induced MMP13 cleavage 
in conditioned media of human VSMCs, and mouse VSMCs 
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Figure 1. FOXO3a (forkhead transcription 
factor O subfamily member 3a) activa-
tion stimulates MMP (matrix metallopro-
teinase) expression and activation. A, 
Quantitative polymerase chain reaction 
for mmp13 mRNA of wild-type (WT) or 
FOXO3aA3ER vascular smooth muscle 
cells (VSMCs; FOXO) treated with ethanol 
carrier control (−) or hydroxytamoxifen 
(HT; +) from 0 to 24 h. B, Western blot of 
conditioned media (top) and cell lysates 
(bottom) of FOXO3aA3ER VSMCs from 
4 to 24 h. C, Zymogram of MMP activ-
ity in conditioned media from WT or 
FOXO3aA3ER VSMCs after carrier control 
(−) or HT (+) for 24 h. D, Zymogram of 
MMP13 activity after immunoprecipitation 
of conditioned medium with IgG control 
or MMP13 antibody after carrier control 
(−) or HT (+) for 24 h. E, Fluorogenic 
dye-quenched (DQ) gelatin fluorescence 
of WT or FOXO3aA3ER VSMCs treated 
with HT for 16 h. Insets show DAPI 
(4’,6-diamidino-2-phenylindole) of same 
field as DQ gelatin. Data are means±SD, 
n=3. *P<0.001 vs time 0.
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behaved similarly (Figure 2F). FOXO3a siRNA reduced 
MMP13 in the conditioned media (Figure V in the online-
only Data Supplement). Both SF and SFGF increased gelatin 
degradation, indicating significant MMP activity (Figure 2G 
and 2H), and both SF and SFGF induced apoptosis in human 
VSMCs (Figure 2I).
To ensure that MMP13 induction was not related to lack 
of glucose in the culture medium, we examined MMP13 in 
human VSMCs after PI-3  (phosphoinositide 3-kinase) kinase 
inhibition using LY294002. LY294002 caused complete 
FOXO3a dephosphorylation in SF medium with no changes in 
expression of FOXO3a, FOXO1, or FOXO4 (Figure VIA and 
VIB in the online-only Data Supplement). FOXO3a siRNA 
was specific for FOXO3a, and LY294002 induced MMP13 
expression in the conditioned medium that was reduced by 
FOXO3a siRNA (Figure VIC and VID in the online-only 
Data Supplement). Both LY294002-induced MMP13 activ-
ity on zymography and apoptosis were reduced by siRNA 
BA
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Figure 2. MMP13 (matrix metalloproteinase 13) is a direct target of FOXO3a (forkhead transcription factor O subfamily member 3a). A, 
Dual luciferase assay of wild-type (WT) control or FOXO3aA3ER (FOXO) vascular smooth muscle cells (VSMCs) treated with carrier con-
trol (−) or hydroxytamoxifen (HT; +) for 24 h after transfection of plasmids containing a promoter construct containing a forkhead response 
element (FHRE) or a MMP3, 9, 13, or 2 promoter. B, Dual luciferase assay of WT or FOXO3aA3ER (FOXO) VSMCs treated with carrier 
control (−) or HT (+) after transfection with a −1600 MMP13 promoter fragment or after point mutation of the FOXO3a-binding site. C and 
D, Western blot for MMP13 in conditioned media or lysates (C), or zymography of conditioned media (D) of FOXO3aA3ER VSMCs after 
transfection with either control siRNA or siRNA to human FOXO3a and 24 h treatment with HT. E, Western blot of lysates from human 
VSMCs incubated in medium containing 10% FCS, 0% FCS (serum free [SF]), or SF and glucose-free medium (SFGF) for 24 h for phos-
phorylated and unphosphorylated FOXO3a. F, Western blot for MMP13 of conditioned media from mouse or human VSMCs in SF or 
SFGF media compared with FOXO3aER VSMCs±hydroxytamoxifen (OHT) for 24 h. G, Fluorescence microscopy for DG-gelatin of human 
VSMCs in E, quantified in H. I, Percentage of apoptotic cells by flow cytometry of human VSMCs in E. Data are means±SD, n=3.
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to FOXO3a, or the MMP13-selective inhibitor WAY170523 
(Figure VIE through VIH in the online-only Data Supplement), 
confirming that activation of endogenous levels of FOXO3a 
induces MMP13 expression and activity in human VSMCs, 
which is sufficient to promote apoptosis.
FOXO3a-Induced Apoptosis Is Mediated, 
in Part, by MMP13-Induced ECM 
Degradation and Fibronectin Cleavage
Although FOXO3a induces transcription of many proapop-
totic genes, the ECM also provides survival signals, such that 
degradation of ECM proteins may promote VSMC apoptosis. 
To determine whether FOXO3a-induced MMP13 degrades 
ECM survival proteins, we first examined a range of MMP 
inhibitors on FOXO3a-induced MMMP13 activation and 
activity, including the broad-spectrum MMP inhibitors 
GM6001 and Batimastat, the MMP13-selective inhibitors 
WAY170523 and M13i, and the serine protease inhibitor 
aprotinin. In particular, WAY170523 has an IC50 of 17 nM for 
MMP13 with >5800-, 56-, and >500-fold selectivity against 
MMP1, MMP9, and TACE (TNF-α–converting enzyme), 
respectively.18 GM6001, Batimastat and WAY170523 inhib-
ited MMP13 cleavage in conditioned media and activity on 
zymography, whereas M13i partly reduced MMP13 cleav-
age but not its activity (Figure VII in the online-only Data 
Supplement). WAY170523 had minor effects on MMP2 
cleavage and activity, but WAY170523 and GM6001 both sig-
nificantly inhibited fluorogenic dye-quenched gelatin cleav-
age (Figure VII in the online-only Data Supplement) and 
apoptosis (Figure VII in the online-only Data Supplement) 
induced by hydroxytamoxifen treatment of FOXO3aA3ER 
cells. Our data suggest that WAY170523 is an irreversible 
inhibitor of MMP13 and that FOXO3a-induced MMP13 pro-
vides the primary gelatin-cleaving activity.
The ECM contains proteins that protect VSMCs against 
apoptosis, including fibronectin and N-cadherin, both of 
which may be targets of FOXO3a and MMPs,16,19 albeit in 
other cell types and cleaved by different MMPs. Fibronectin 
is a ligand for surface integrins and has a prominent role in 
cell adhesion. Hydroxytamoxifen treatment of FOXO3aA3ER 
VSMCs reduced fibronectin intercellular bridges (Figure VIII 
in the online-only Data Supplement), and caused fibronectin 
cleavage, which was inhibited by FOXO3a or MMP13 siRNA, 
or treatment with WAY170523. Fibronectin also potently pro-
tected VSMCs from FOXO3a-induced apoptosis when pre-
coated onto the culture plate. In contrast, FOXO3a activation 
did not induce N-cadherin cleavage (Figure VIII in the online-
only Data Supplement).
SM22αFOXO3aA3ER Mice
To examine the role of FOXO3a in VSMCs in vivo, we gener-
ated SM22αFOXO3aA3ER transgenic mice. Haemagglutinin-
tagged FOXO3aA3ER was coupled to the minimal SM22α 
promoter lacking the G/C-rich repressor region (−256 to −249; 
Figure 3A). This promoter (−447 to +89 relative to the tran-
scriptional start site) directs expression of transgenes only to 
VSMCs of large- and medium-sized arteries in adult mice, with 
no expression in venous or visceral SMCs,20 whereas G/C-rich 
region mutation prevents promoter downregulation in athero-
sclerosis and vessel remodeling.21 Two SM22αFOXO3aA3ER 
founder lines were established, which were viable, fertile, 
transmitted the transgene normally, and had no overt pheno-
type without tamoxifen. SM22αFOXO3aA3ER was expressed 
only in arteries, but not in heart, liver, or gut (Figure 3B), and in 
cultured VSMCs of transgenic but not littermate control mice. 
SM22αFOXO3aA3ER activation did not affect expression of 
other FOXO species but induced bim, gadd45α, mmp2, and 
mmp13 and also induced apoptosis (Figure IX in the online-
only Data Supplement). Thus, SM22αFOXO3aA3ER is 
expressed, activated by hydroxytamoxifen, and induces tran-
scription of FOXO3a target genes and apoptosis in VSMCs 
both in vitro and in vivo.
We treated SM22αFOXO3aA3ER and wild-type litter-
mate control mice with tamoxifen (1 mg immunoprecipitation 
daily for 3 days) and examined FOXO3a expression, FOXO3a 
nuclear localization, and apoptosis in aortas at 7 days. 
FOXO3aA3ER expression was evident in transgenic mouse 
aortas at low levels compared with endogenous FOXO3a 
and with no change in expression of endogenous FOXO3a 
(Figure 3C). Tamoxifen treatment resulted in predominantly 
nuclear FOXO3a localization in SM22αFOXO3aA3ER mice 
compared with predominantly cytoplasmic localization in con-
trol mice (Figure 3D; quantified in Figure IXD in the online-
only Data Supplement). In SM22αFOXO3aA3ER mouse 
aortas, Tamoxifen induced VSMC apoptosis (Figure 3E and 
3F), increased mmp13 mRNA expression 4-fold, and also 
induced MMP13 protein expression (Figure 3G) and activ-
ity (Figure 3H). MMP13 activity could be inhibited by con-
comitant treatment with WAY170523, which had no effect on 
MMP2 or MMP9 activity (Figure 3H).
FOXO3a Activation Leads to VSMC 
Apoptosis and Promotes Atherosclerosis
To examine the effect of FOXO3a activation during athero-
genesis, SM22αFOXO3aA3ER mice were crossed with 
ApoE−/− (apolipoprotein E deficient) mice, and homozygous 
male SM22αFOXO3aA3ER/ApoE−/− or littermate control 
ApoE−/− mice were fat fed for 14 weeks from 8 to 22 weeks 
of age. Both groups received hydroxytamoxifen administered 
triweekly for 14 weeks and bromodeoxyuridine for the last 2 
weeks. Serum lipids were measured before and after 7 and 14 
weeks of fat feeding. Blood pressure was measured by tail cuff. 
Atherosclerosis was examined in the aortic roots, brachioce-
phalic arteries, and descending aorta at 22 weeks (14 weeks of 
fat feeding), which show different degrees of plaque develop-
ment. Body weight, serum lipids (Table III in the online-only 
Data Supplement), heart rate, blood pressure (Table IV in the 
online-only Data Supplement), and a range of serum inflamma-
tory cytokines (Table V in the online-only Data Supplement) 
were similar in ApoE−/− and SM22αFOXO3aA3ER/ApoE−/− 
mice. However, SM22αFOXO3aA3ER/ApoE−/− mice had 
significantly increased atherosclerosis in all 3 vascular beds 
(Figures 4, 5A, and 5B; Figure X in the online-only Data 
Supplement; Table VI in the online-only Data Supplement). 
SM22αFOXO3aA3ER/ApoE−/− mice had increased necrotic 
core areas (absolute and core:plaque ratio), reduced relative 
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fibrous cap areas (cap:core and cap:plaque ratios), and more 
apoptosis (Figure 5C through 5F; Table VI in the online-only 
Data Supplement). SM22αFOXO3aA3ER/ApoE−/− mice also 
had reduced aortic media VSMC number, with increased elas-
tin breaks (Figure 5G and 5H; Figure XI in the online-only 
Data Supplement), but we did not observe aneurysm forma-
tion, aortic dissection, or rupture.
FOXO3a Activation Promotes 
Apoptosis and Neointima Formation, 
Mediated, in Part, by MMP13
Our data indicate that FOXO3a activation induces apoptosis 
and MMP13 activity in vitro and in vivo that can be inhib-
ited by the MMP13 inhibitor WAY170523 and promotes 
atherogenesis, increased necrotic core area, reduced relative 
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Figure 3. Vascular smooth muscle cell–specific expression of FOXO3aA3ER induces apoptosis in vivo. A, Structure of the 
SM22αFOXO3aA3ER transgene. B, Reverse-transcriptase polymerase chain reaction for FOXO3aA3ER in aorta, heart, liver, and gut of 2 
SM22αFOXO3aA3ER founder mice or a littermate control. Genomic DNA from SM22αFOXO3aA3ER or littermates were used as positive (+) or 
negative controls (−). C and D, Western blot (C) or immunohistochemistry (D) for FOXO3a (forkhead transcription factor O subfamily member 
3a) in littermate control or SM22αFOXO3aA3ER (FOXO) mouse aortas at 7 d after tamoxifen treatment. E and F, TUNEL (terminal UTP nick-
end labeling) of control or SM22αFOXO3aA3ER mouse aortas at 7 d after tamoxifen. G, Immunohistochemistry for MMP13 (matrix metallo-
proteinase 13) in SM22αFOXO3aA3ER mouse aortas after 5 d of vehicle control or tamoxifen. H, In situ zymography of SM22αFOXO3aA3ER 
mouse aortas after 5 d of tamoxifen±WAY170523 (WAY). Scale bars, 25 µm in D and 100 µm in E and G. Data are means±SD, n=6. I, Negative 
and positive controls for MMP13 antibody staining of lymph node. Scale bar, 50 µm. HA indicates haemagglutinin.
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fibrous cap area, increased apoptosis, and medial degenera-
tion. However, it does not identify whether MMP13 mediates 
any of the effects of FOXO3a activation in vivo. We, therefore, 
examined the effect of FOXO3a on remodeling after carotid 
artery ligation—a well-established model that features medial 
VSMC apoptosis and MMP activation.22 Both final vessel 
caliber and neointimal size are regulated by VSMC apoptosis 
in this model,23 and the neointima formed is mostly VSMCs 
derived from the media.24 Male SM22αFOXO3aA3ER and 
control littermate mice aged between 5 and 6 months under-
went carotid artery ligation followed by tamoxifen treatment 
3× per week to ensure that FOXO3aER is activated through-
out the whole time course during remodeling, with or without 
WAY170523 administered continuously by osmotic mini-
pump from days 0 to 7 after ligation, at a WAY170523 con-
centration that inhibits MMP13 activity in vivo (Figure 3H). 
Bromodeoxyuridine was administered throughout. FOXO3a 
activation increased intimal area and cell count compared with 
control vessels—an effect that was reduced by WAY170523—
with no effect of FOXO3a activation or WAY170523 on lumen 
area, medial area, or medial cell count (Figure 6; Table VII 
in the online-only Data Supplement). However, WAY170523 
reduced medial cellularity, suggesting that it protects against 
matrix degradation. FOXO3a activation increased VSMC pro-
liferation, which was also reduced by WAY170523 (Figure 6; 
Table VII in the online-only Data Supplement). WAY170523 
did not affect intimal or medial areas or cell proliferation in 
the absence of FOXO3a activation in control mice. In contrast, 
FOXO3a activation in SM22αFOXO3aA3ER mice increased 
apoptosis compared with control mice, and WAY170523 
reduced apoptosis in both control and SM22αFOXO3aA3ER 
mice (Figure 6; Table VII in the online-only Data Supplement).
Discussion
FOXO3a activity is increased in VSMCs in human athero-
sclerotic plaques, and previous studies have demonstrated that 
Akt1 in VSMCs protects against atherosclerosis4,5,25,26; how-
ever, the major targets of Akt protection in atherosclerosis are 
not known. Specifically, FOXO3a has multiple transcriptional 
targets in a large range of cellular processes, and its effects 
are cell type specific. Both apoptosis and MMP activity occur 
in human plaques and often colocalize to the necrotic core, 
where they have been ascribed to macrophages. However, 
although VSMCs can generate foam cells in atherosclerosis,27 
no link between VSMC apoptosis and MMP expression or 
activity has been shown or the mechanism determined.
There are several important findings from our study. 
FOXO3a activation markedly induces MMP13 expression and 
secretion from VSMCs, and MMP13 (but not MMP3 or 9) is 
a direct FOXO3a transcriptional target in VSMCs. FOXO3a 
       ApoE-/-           SM22 FOXO3aA3ERTM/ ApoE-/-
Massons 
SMA 
Mac3 
TUNEL 
IgG 
IgG 
IgG 
Figure 4. FOXO3a (forkhead transcription 
factor O subfamily member 3a) activa-
tion promotes atherosclerosis, increased 
necrotic cores, and apoptosis. Histo-
chemistry and immunohistochemistry of 
aortic root plaques of control ApoE−/− or 
SM22αFOXO3aA3ER/ApoE−/− mice after 
14 wk of fat feeding+tamoxifen. Sec-
tions were stained with H+E, Massons, 
or antibodies to α-SMA (smooth muscle 
cell α actin), mac3, or underwent TUNEL 
(terminal UTP nick-end labeling). Scale 
bar, 500 μm. Insets are high power view 
of area outlined in the main panel. Right, 
Negative control sections for SMA, mac3, 
and TUNEL.
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reduces TIMP1-3 expression at both RNA and protein levels, 
which could further increase MMP activity. FOXO3a activation 
causes VSMC apoptosis and ECM breakdown, both of which, 
in part, require MMP13. Importantly, activation of endogenous 
levels of FOXO3a induces MMP13 expression, secretion, acti-
vation, ECM breakdown, and apoptosis, and MMP13 inhibitors 
reduce FOXO3a-induced apoptosis, confirming that FOXO3a-
mediated apoptosis in VSMCs is because of both induction 
of conventional proapoptotic genes and MMP-induced ECM 
breakdown of protective proteins, including fibronectin. 
FOXO3a activation in SM22αFOXO3aA3ER mice induces 
VSMC apoptosis, increases MMP13 expression and activity, 
promotes atherosclerosis, increases necrotic core and reduces 
relative fibrous cap areas, and promotes medial degeneration. 
Finally, FOXO3a activation in VSMCs increases intimal for-
mation, associated with increased apoptosis and compensatory 
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Figure 5. Quantification of size and composition in mouse plaques. A and B, Plaque size and composition of aortic root (A), or brachioce-
phalic plaques (B) of control ApoE−/− or SM22αFOXO3aA3ER/ ApoE−/− mice after 14 wk of fat feeding. n=11 to 15 (aortic), n=8 (brachioce-
phalic). C–F, Plaque composition of aortic root plaques or (G) medial cell counts or (H) elastin breaks in undiseased aortas of experimental 
mice. Data are means±SD, n=11 to 14. FOXO indicates forkhead transcription factor O subfamily; and TUNEL, terminal UTP nick-end labeling.
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increased VSMC proliferation; MMP13 inhibition reduces 
VSMC apoptosis and intimal and medial VSMC proliferation 
induced by FOXO3a and reduces neointima formation.
The MMPs are 23 secreted or cell surface proteases 
that hydrolyze ECM components. MMP groups are based 
on overlapping ECM substrates, for example, collagenase 
(MMP1, 8, 13), gelatinases (MMP2, 9), and stromelysins 
(MMP3, 7, 10, 11). MMPs may facilitate VSMC migration 
and vessel remodeling in early atherosclerosis but degrade 
ECM in advanced plaques to promote plaque vulnerability.28 
Expression of some MMPs is increased in atherosclerosis 
together with reduction in TIMPs in both mice and humans, 
associated with increased conversion of zymogens to activated 
proteases.28 In particular, atherosclerotic plaques and arterial 
aneurysms have increased MMP13 activity,29,30 and MMP13-
null mice have increased fibrillar collagen.31,32 Although these 
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Figure 6. Effects of FOXO3 (forkhead transcription factor O subfamily member 3) activation and MMP13 (matrix metalloprotein-
ase 13) inhibition on arterial remodeling. A, Histochemistry and immunohistochemistry of left carotid artery at 28 d post-ligation of 
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tal mice as in A. Data are means±SEM, n=6 to 11.
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findings suggest that MMP13 may be important in athero-
sclerosis, previous studies have identified macrophages as 
the likely source,29 and MMP13 has not been linked with 
FOXO3a activation in VSMCs. In contrast, although the abso-
lute increase in mmp13 mRNA by array or  quantitative poly-
merase chain reaction differed, most likely related to different 
techniques, we show that FOXO3a activation caused marked 
release and activity of MMP13 from VSMCs.
The endogenous pathways that protect against VSMC 
apoptosis in atherosclerosis have not been studied extensively. 
We find that FOXO3a activation induces apoptosis and ECM 
degradation through MMP13 in transgenic mice and cultured 
VSMCs expressing a constitutively active chimeric protein 
but importantly also with endogenous levels of FOXO3a. 
Endogenous FOXO3a is activated in human atherosclero-
sis,14 and in culture induces MMP13 induction and secre-
tion, ECM breakdown, and VSMC apoptosis. Endogenous 
FOXO3a inhibitors are also reduced in atherosclerosis and 
plaque VSMCs, including Akt13–15 and the deacetylase sir-
tuin 1.33,34 Indeed, VSMC-specific SIRT1 deletion promotes 
atherosclerosis, VSMC apoptosis, and marked medial degen-
eration, elastin breaks and aneurysm formation in mice.34 The 
combination of reduced FOXO3a inhibitors, increased MMP 
activation, and reduced TIMP expression induced by FOXO3a 
would have profound effects on ECM integrity in atheroscle-
rosis in vivo. In addition, as VSMCs synthesize ECM in the 
vessel wall, FOXO3a-induced VSMC apoptosis might further 
reduce ECM formation.
We find major effects of FOXO3a in vessel remodeling and 
neointima formation after carotid artery ligation. This model is 
characterized by MMP9 activity (days 1–3), VSMC apoptosis 
(days 2–14), and MMP2 activity (days 14–28), associated with 
medial recovery, neointimal formation, and arterial remodel-
ing.22 Augmenting VSMC apoptosis significantly increases cell 
proliferation—an example of apoptosis-induced compensatory 
proliferation, cell migration, and ECM synthesis, resulting in 
increased neointimal and medial areas.23 We find that FOXO3a 
activation increases neointima formation, intimal and medial 
proliferation, and VSMC apoptosis, all of which were reduced 
by MMP13 inhibition, indicating that MMP13 partly regulates 
the effect of FOXO3a activation on remodeling.
There are several limitations to our study. For example, 
we used an overexpression system both in vitro and in vivo to 
examine FOXO3a effects in VSMCs, which may not be sub-
ject to the same regulatory controls and, therefore, not truly 
reflect activation of endogenous FOXO3a. However, the levels 
of transgene expression in vivo are low, and we show that acti-
vation of FOXO3aA3ER and LY294002-induced FOXO3a 
activation do not result in compensatory changes in expres-
sion of other FOXO species. In addition, our studies have 
focused on the effects of FOXO3a activation in advanced ath-
erosclerosis and have not examined early phases of atherogen-
esis. However, FOXO3a is not activated until later stages of 
atherosclerosis,14 and VSMC apoptosis is not seen in human 
atherosclerosis until advanced lesions are present.35
The presence of activated FOXO3a in atherosclerosis14 and 
the marked activation and effects of MMP13 might suggest 
that MMPs in general and MMP13 in particular are attrac-
tive therapeutic targets. However, no MMP inhibitor has been 
approved clinically for atherosclerosis,36 which may reflect 
differing roles of MMPs in plaque development, MMP redun-
dancy with overlapping substrates, and nonspecificity/toxicity 
of current available inhibitors. Although MMP12 and MMP13 
may be more promising targets,37 altering the balance of 
MMPs and TIMPs by inhibiting FOXO3a may be more effec-
tive, such as by preventing Akt and SIRT1 downregulation.
In conclusion, we show that FOXO3a activation induces 
VSMC apoptosis, in part, through regulating MMP13 and 
MMP inhibitors to promote ECM degradation. Activation 
of endogenous FOXO3a, as seen in human atherosclerosis, 
is sufficient to induce apoptosis, MMP activation, and ECM 
degradation. FOXO3a activation promotes atherosclerosis 
and medial degeneration, together with increased necrotic 
cores and reduced relative fibrous cap areas, and FOXO3a 
and MMP13 regulate arterial remodeling. FOXO3a-induced 
MMP13 activation and TIMP downregulation provide an 
important mechanism that directly links VSMC apoptosis and 
ECM degradation in vascular disease.
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Highlights
• The transcriptional factor FOXO3a (forkhead transcription factor O subfamily member 3a) is increased in human atherosclerosis compared with 
normal vessels, but its role in atherosclerosis and vascular remodeling is unknown.
• FOXO3 activation in vascular smooth muscle cells induces MMP13 (matrix metalloproteinase 13) and reduces MMP inhibitors, causing degra-
dation of the extracellular matrix and survival proteins.
• FOXO3a activation in vivo induces vascular smooth muscle cell apoptosis, promotes atherosclerosis, increases necrotic core, and reduces 
relative fibrous cap areas.
• FOXO3a activation after arterial ligation promotes neointimal formation, in part, regulated by MMP13.
• The FOXO3a-MMP13 axis directly links vascular smooth muscle cell apoptosis and matrix breakdown in atherosclerosis and vascular remod-
eling.
